LooareesuwanTHI95.

Methods	Computer generated randomisation in blocks of 10, allocation concealed in sealed envelopes, physicians and technicians blinded No exclusions reported Loss to follow‐up at 28 d: AS1600 = 5/32 (16%), AS1200 = 4/31 (13%)
Participants	63 Thai adults > 15 years Severe falciparum malaria (WHO 1990b) 51/63 had not had malaria before Excluded: pregnancy; acute diarrhoea; rectal abnormalities or previous surgery; antimalarials in previous 2 weeks
Interventions	ASpr1200 + MQ25 vs ASpr1600 + MQ25: 1. AS1200: 200 mg at 0 h, 12 h, 24 h, 36 h, 48 h and 60 h + MQ1250 mg (sequential, 750 mg at 72 h & 500 mg at 84 h) 2. AS1600: 200 mg at 0 h, 4 h, 8 h, 12 h, 24 h, 36 h, 48 h and 60 h + MQ1250 (as before)
Outcomes	1. Mortality 2. Time to regain consciousness 3. FCT 4. PCT (50, 90, 100%) 5. Cure rate at day 28 6. Adverse effects
Notes	Quality assessment: A, A, B AS: Plasmotrim, Rectocaps (200 mg capsule) Mepha, Switzerland